1. Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol. 1984; 148:886–94.
2. Chao AS, Chung CL, Wu CD, Chang SD, Cheng PJ, Lin YT, et al. Second trimester maternal serum screening using alpha fetoprotein, free beta human chorionic gonadotropin and maternal age specific risk: result of chromosomal abnormalities detected in screen positive for Down syndrome in an Asian population. Acta Obstet Gynecol Scand. 1999; 78:393–7.
Article
3. Haddow JE, Palomaki GE, Knight GJ, Williams J, Pulkkinen A, Canick JA, et al. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med. 1992; 327:588–93.
Article
4. Benn PA, Horne D, Briganti S, Greenstein RM. Prenatal diagnosis of diverse chromosome abnormalities in a population of patients identified by triple-marker testing as screen positive for Down syndrome. Am J Obstet Gynecol. 1995; 173:496–501.
Article
5. Suzumori K, Tanemura M, Murakami I, Okada S, Natori M, Tanaka M, et al. A retrospective evaluation of maternal serum screening for the detection of fetal aneuploidy. Prenat Diagn. 1997; 17:861–6.
Article
6. Ogle R, Jauniaux E, Pahal GS, Dell E, Sheldrake A, Rodeck C. Serum screening for Down syndrome and adverse pregnancy outcomes: A case-controlled study. Prenat Diagn. 2000; 20:96–9.
Article
7. Cha YJ, Yang JS, Chae SL, Park AJ. An evaluation of prenatal triple marker screening. Korean J Lab Med. 2003; 23:199–204.
8. Gardner RJM, Sutherland GR. Chromosome abnormalities and genetic counseling. 2nd ed.New York: Oxford University Press;1996. p. 349–52.
9. Dimaio MS, Baumgarten A, Greenstein RM, Saal HM, Mahoney MJ. Screening for fetal Down's syndrome in pregnancy by measuring maternal serum alpha-fetoprotein levels. N Engl J Med. 1987; 317:342–6.
Article
10. Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn. 1987; 7:623–30.
Article
11. Saller DN Jr, Canick JA, Schwartz S, Blitzer MG. Multiple marker screening in pregnancies with hydropic and nonhydropic Turner syndrome. Am J Obstet Gynecol. 1992; 167:1021–4.
12. Hogge WA, Fraer L, Melegari T. Maternal serum screening for fetal trisomy 18: benefits of patient-specific risk protocol. Am J Obstet Gynecol. 2001; 185:289–93.
Article
13. Zanini R, Tarantini M, Cerri V, Jacobello C, Bellotti D, Lancetti S, et al. 'Dual positivity'for neural tube defects and down syndrome at maternal serum screening: gestational outcome. Fetal Diagn Ther. 1998; 13:106–10.
14. Summers AM, Huang T, Wyatt PR. Pregnancy outcomes of women with positive serum screening results for Down syndrome and trisomy 18. Prenat Diagn. 2002; 22:269–71.
Article
15. Yang YH, Yang ES, Park YW, Kim SK, Kim IK, Son YS. Clinical and cytogenetic study on 3,672 genetic amniocentesis: YUMC 20 years experience from 1985 to 2004 years. Korean J Obstet Gynecol. 2005; 48:1663–72.
16. Chen CP, Chern SR, Tsai FJ, Lin CY, Lin YH, Wang W. A comparison of maternal age, sex ratio and associated major anomalies among fetal trisomy 18 case with different cell division of error. Prenat Diagn. 2005; 25:327–30.
17. Borrell A, Gonce A, Martinez JM, Borobio V, Fortuny A, Coll O, et al. First-trimester screening for Down syndrome with ductus venosus Doppler studies inaddition to nuchal translucency and serum markers. Prenat Diagn. 2005; 25:901–5.
18. Filkins K, Koos BJ. Ultrasound and fetal diagnosis. Curr Opin Obstet Gynecol. 2005; 17:185–95.
Article
19. Porto M, Murata Y, Warneke LA, Keegan KA Jr. Fetal choroid plexus cysts: an independent risk factor for chromosomal anomalies. J Clin Ultrasound. 1993; 21:103–8.
Article